President Donald Trump is keeping up the pace with seemingly a new tariff development every day. This time, he flagged that ...

Finally, don't discount legal challenges to the president's tariffs. An argument could be made that pharmaceutical products ...

W hen Donald Trump’s tariffs are mentioned, you might recall his “Liberation Day” duties on uninhabited islands, his on-again ...

President Trump is reportedly pushing for higher blanket tariffs on imports from the European Union, throwing a wrench in ...

Australia’s pharmaceutical benefits scheme is not up for negotiation, says the federal government in the face of ramped-up US ...

The opening salvo of second-quarter earnings calls this week came against President Donald Trump’s renewed calls for a tariff ...

A 200% tariff rate — even with a delay — will have a detrimental effect on drug prices and profit margins, analysts warn.

Johnson & Johnson beat Wall Street’s quarterly sales expectations and raised its full-year outlook, a show of confidence as the pharmaceutical industry faces the dual threats of tariffs and a ...

Despite the threat of a 200% tariff, most pharma stocks remained stable. US President Donald Trump’s 200% tariff threat on the pharmaceutical industry is a “shock” that will reverberate through global ...

Already late with carrying out his administration's prior threats around pharmaceutical tariffs, President Donald Trump has ...

Swiss drugmaker Novartis nudged up its full-year earnings forecast on Thursday, citing strong second-quarter sales of key ...

Drugmaker Swedish Orphan Biovitrum AB’s Chief Executive Officer Guido Oelkers said he doesn’t think tariff threats on the ...